Atsushi Hirano

Atsushi Hirano

Auto-generated profile, based on publicly available information

Atsushi Hirano

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
AHAtsushi Hirano
Atsushi Hirano
JUJunji Umeno
Junji Umeno
YOYasuharu Okamoto
Yasuharu Okamoto
HSHiroki Shibata
Hiroki Shibata
YOYoshitoshi Ogura
Yoshitoshi Ogura
MEMotohiro Esaki
Motohiro Esaki

7 August 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
YMYuichi Matsuno
Yuichi Matsuno
AHAtsushi Hirano
Atsushi Hirano
TTTakehiro Torisu
Takehiro Torisu
YOYasuharu Okamoto
Yasuharu Okamoto
YFYuta Fuyuno
Yuta Fuyuno
MEMotohiro Esaki
Motohiro Esaki

30 April 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
YMYuichi Matsuno
Yuichi Matsuno
TTTakehiro Torisu
Takehiro Torisu
JUJunji Umeno
Junji Umeno
HSHiroki Shibata
Hiroki Shibata
AHAtsushi Hirano
Atsushi Hirano
TKTakanari Kitazono
Takanari Kitazono
Background/Aims: Recent studies suggested a favorable effect of indigo naturalis (IN) in inducing remission for refractory ulcerative colitis (UC), however, the maintenance effect of IN for patients with UC remains unknown. Therefore, we conducted a prospective uncontrolled open-label study to analyze the efficacy and safety of IN for patients with UC.Methods: Patients with moderate to severe active UC (clinical activity index [CAI] ≥ 8) took 2 g/day of IN for 52 weeks. CAI at weeks 0, 4, 8, and 52 and Mayo endoscopic subscore (MES) and Geboes score (GS) at weeks 0, 4, and 52 were assessed. Clinical remission (CAI ≤ 4), mucosal healing (MES ≤ 1), and histological healing (GS ≤ 1) rates at each assessment were evaluated. Overall adverse events (AEs) during study period were also evaluated. The impact of IN on mucosal microbial composition was assessed using 16S ribosomal RNA gene sequences.Results: Thirty-three patients were enrolled. The rates of clinical remission at weeks 4, 8, and 52 were 67%, 76%, and 73%, respectively. The rates of mucosal healing at weeks 4 and 52 were 48% and 70%, respectively. AEs occurred in 17 patients (51.5%) during follow-up. Four patients (12.1%) showed severe AEs, among whom 3 manifested acute colitis. No significant alteration in the mucosal microbial composition was observed with IN treatment.Conclusions: One-year treatment of moderate to severe UC with IN was effective. IN might be a promising therapeutic option for maintaining remission in UC, although the relatively high rate of AEs should be considered.



22 May 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
YIY Ihara
Y Ihara
AHA Hirano
A Hirano
SES Endo
S Endo
HKH Kobayashi
H Kobayashi
TTT Torisu
T Torisu